Curevac announces financial results for the fourth quarter and full-year 2023 and provides business update

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs together with gsk, ended pandemic preparedness agreement (ppa) with federal republic of germany, after consultation with the german federal ministry of health cash and cash equivalents position of €402.5 million as of december 31, 2023; cash runway extended into q4 2025 with organizational redesign and despite ppa wind-down strategic collaboration signed with world-leading oncology center md anderson, creating unique expertise to jointly discover and develop novel cancer vaccines appointment of thaminda ramanayake as chief business officer, bringing more than 15 years of biopharma company development and deal-making experience promising covid-19 and seasonal flu phase 2 data confirms proprietary mrna platform elicits strong overall antibody titers at well-tolerated dose levels new phase 1/2 study in avian flu started in collaboration with gsk addressing potential future pandemic threat successful safety review of data from glioblastoma phase 1 part a with multiepitope cancer vaccine candidate, cvgbm, enables progressing to part b with expected start mid-2024 curevac to host conference call and webcast today at 9 a.m. et / 3 p.m.
CVAC Ratings Summary
CVAC Quant Ranking